$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

250万美元预付款，若短期认股权证全额行使，还可获得高达460万美元的潜在总收益。

STATEN ISLAND, N.Y.

纽约州斯塔滕岛

,

，

April 16, 2026

2026年4月16日

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:

/PRNewswire/ -- Acurx Pharmaceuticals, Inc.（纳斯达克：

ACXP

ACXP

) ('we' or 'Acurx' or the 'Company'), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

）（“我们”或“Acurx”或“公司”），一家处于后期阶段的生物制药公司，正在开发一类用于治疗难治性细菌感染的新型抗生素，今天宣布已达成一项最终协议，将在一项按照纳斯达克规则定价的市价注册直接发行中，以每股3.03美元的价格（或预融资认股权证代替）出售总计825,085股普通股（或预融资认股权证代替）。

In addition, in a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 1,650,170 shares of common stock. The short-term warrants will have an exercise price of $2.78 per share, will be immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement registering the resale of the shares of common stock underlying the short-term warrants.

此外，在同期进行的私募中，公司将发行未注册的短期认股权证，可购买多达1,650,170股普通股。这些短期认股权证的行权价格为每股2.78美元，将在发行后立即可行权，并在登记声明生效日期后二十四个月到期，该登记声明用于登记与短期认股权证相关的普通股转售。

The closing of the offering is expected to occur on or about April 16, 2026, subject to the satisfaction of customary closing conditions..

预计此次发行的结束将在2026年4月16日或左右完成，但需满足惯例的交割条件。

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

H.C. Wainwright & Co. 担任此次发行的独家配售代理。

The aggregate gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the unregistered short-term warrants, if fully-exercised on a cash basis, will be approximately $4.6 million.

预计公司此次发行的总收入在扣除公司应支付的配售代理费和其他发行费用前约为250万美元。如果未注册的短期权证全额行使且以现金为基础，公司可能获得的额外潜在总收入将约为460万美元。

No assurance can be given that any of such short-term warrants will be exercised. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes..

无法保证这些短期认股权证中的任何一个会被行使。公司目前打算将此次发行的净收益用于营运资金和其它一般企业用途。

The shares of common stock (or pre-funded warrants) (but not the short-term warrants issued in the private placement or the shares of common stock underlying such short-term warrants) are being offered by the Company pursuant to a 'shelf' registration statement on Form S-3 (File No. 333-288595) filed with the Securities and Exchange Commission ('SEC') on July 9, 2025, and became effective on January 6, 2026.

本公司根据于2025年7月9日向美国证券交易委员会（“SEC”）提交的S-3表格（文件编号333-288595）上的“货架”注册声明，以及于2026年1月6日生效的声明，发行普通股（或预融资认股权证）（但不包括私募发行中的短期认股权证或该等短期认股权证所对应的普通股）。

The registered direct offering of the shares of common stock (or pre-funded warrants) is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered in the registered direct offering will be filed with the SEC and be available at the SEC's website at .

仅通过招股说明书（包括招股说明书补充文件）来进行普通股（或预融资认股权证）的注册直接发行，该招股说明书是有效注册声明的一部分。与注册直接发行中所提供的证券相关的招股说明书补充文件及随附的招股说明书将提交给美国证券交易委员会（SEC），并在SEC的网站上提供。

www.sec.gov

www.sec.gov

. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at

与注册直接发行相关的招股说明书补充文件和附带的招股说明书的电子副本，在可供获取时，也可以通过联系H.C. Wainwright & Co., LLC获取，地址为纽约州纽约市公园大道430号三楼，邮编10022，电话：（212）856-5711，或通过电子邮件

[email protected]

电子邮件地址

.

。

The short-term warrants described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the short-term warrants, have not been registered under the Securities Act, or applicable state securities laws.

上述短期认股权证正在根据修订后的《1933年证券法》（“证券法”）第4(a)(2)条及其颁布的D条例进行同步私募发行，且这些短期认股权证以及其对应的普通股股份尚未根据《证券法》或适用的州证券法进行注册。

Accordingly, the short-term warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

因此，短期认股权证和标的普通股不得在美国境内发售或出售，除非根据有效的注册声明或适用的《证券法》及相应的州证券法规定的注册要求豁免。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或招揽购买本文所述任何证券的要约，且在任何州或司法管辖区，不得在根据该州或司法管辖区的证券法进行注册或资格认证之前，进行此类要约、招揽或销售，因为此类行为将属违法。

About Acurx Pharmaceuticals, Inc.

关于Acurx制药公司

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death.

Acurx Pharmaceuticals是一家处于后期阶段的生物制药公司，专注于开发一类新型的小分子抗生素，用于治疗难以治愈的细菌感染。该公司采用的方法是开发具有革兰氏阳性选择性谱（GPSS®）的抗生素候选药物，该药物通过阻断革兰氏阳性特异性细菌酶DNA聚合酶IIIC（pol IIIC）的活性位点，抑制DNA复制，从而导致革兰氏阳性细菌细胞死亡。

Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen)..

其研发管线包括针对革兰氏阳性菌的抗生素候选产品，包括艰难梭菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）、耐药肺炎链球菌（DRSP）和炭疽杆菌（炭疽；生物恐怖主义A类威胁病原体）。

Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection (CDI) is Phase 3 ready to advance to international clinical trials subject to obtaining appropriate financing. The Company recently announced the launch of a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one.

Acurx公司的主要候选产品ibezapolstat用于治疗艰难梭菌感染（CDI），已准备好进入第3阶段，即将开展国际临床试验，但需获得适当的资金支持。公司最近宣布启动一项突破性的ibezapolstat临床试验，针对多次复发性CDI（rCDI）患者，该试验有可能将rCDI的治疗和预防模式从两种药物转变为一种药物。

This new clinical trial in rCDI begins with an open-label pilot trial to gain experience with IBZ in patients with multiply-recurrent CDI with at least 3 episodes of CDI within the past 12 months. This will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI indication to be implemented following favorable results from the open-label 20 patient trial.

这项针对复发性艰难梭菌感染（rCDI）的新临床试验首先进行一项开放标签的初步试验，以获取在近12个月内至少发生3次艰难梭菌感染（CDI）的患者中使用IBZ的经验。这将为计划中的活性对照、III期注册试验提供参考依据，该试验将在开放标签的20名患者试验取得积极结果后实施。

Upon subsequent successful completion of the Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (Guidance for Industry, 2020)..

在Ph3关键性rCDI试验后续成功完成后，根据FDA的操作程序，Acurx计划依据FDA的《抗菌和抗真菌药物有限人群途径》（行业指南，2020年）请求FDA批准用于治疗和预防rCDI。

The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

公司的临床前管线包括开发用于治疗ABSSSI（急性细菌性皮肤和皮肤结构感染）的口服候选产品，同时正在计划针对吸入性炭疽的开发项目。

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit

要了解有关Acurx Pharmaceuticals及其产品线的更多信息，请访问

www.acurxpharma.com

www.acurxpharma.com

.

。

Forward-Looking Statements

前瞻性声明

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words 'believes,' 'anticipates,' 'plans,' 'expects,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中关于我们未来预期、计划和前景的任何陈述，包括有关我们的战略、未来运营、前景、计划和目标的陈述，以及其他包含“相信”、“预期”、“计划”、“预计”等类似表述的陈述，均构成《1995年私人证券诉讼改革法案》意义下的前瞻性陈述。

Forward-looking statements include statements regarding the ability of the Company to consummate the offering, the exercise of the short-term warrants prior to their expiration, the satisfaction of the closing conditions of the offering, and the use of proceeds therefrom. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market and other conditions, and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission.

前瞻性声明包括关于公司完成本次发行的能力、短期认股权证在到期前的行使情况、发行交割条件的满足以及发行所得款项用途的声明。由于多种重要因素，实际结果可能与这些前瞻性声明所表明的结果存在重大差异，这些因素包括：市场及其他条件，以及公司在截至2025年12月31日的年度报告中向证券交易委员会提交的Form 10-K表格中描述的其他风险和不确定性，以及公司随后向证券交易委员会提交的文件中所述的内容。

Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law..

本前瞻性声明仅截至本新闻稿发布之日有效，Acurx 公司不承担任何更新这些前瞻性声明的意图或义务以反映在此类声明日期之后发生的事件或情况，除非法律另有要求。

Investor Contact:

投资者联系方式：

Acurx Pharmaceuticals, Inc.

艾큐尔克斯制药公司

David P. Luci, President & Chief Executive Officer

大卫·P·卢西，总裁兼首席执行官

Tel: 917-533-1469

电话：917-533-1469

Email:

电子邮件：

[email protected]

电子邮件地址

SOURCE Acurx Pharmaceuticals, Inc.

来源：Acurx Pharmaceuticals, Inc.

21

21

%

%

more press release views with

更多新闻发布观点

Request a Demo

请求演示